所有图片(1)
About This Item
经验公式（希尔记法）:
C14H11ClN2O4S
CAS号:
分子量:
338.77
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
chlorthalidone
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
NS(=O)(=O)c1cc(ccc1Cl)C2(O)NC(=O)c3ccccc23
InChI
1S/C14H11ClN2O4S/c15-11-6-5-8(7-12(11)22(16,20)21)14(19)10-4-2-1-3-9(10)13(18)17-14/h1-7,19H,(H,17,18)(H2,16,20,21)
InChI key
JIVPVXMEBJLZRO-UHFFFAOYSA-N
基因信息
human ... SLC12A3(6559)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Chlorthalidone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Warning
危险声明
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
靶器官
Respiratory system
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
监管及禁止进口产品
Edarbyclor: an ARB/chlorthalidone combination for hypertension.
The Medical letter on drugs and therapeutics, 54(1385), 17-18 (2012-03-03)
Massimo Cirillo et al.
Hypertension (Dallas, Tex. : 1979), 63(4), 692-697 (2014-01-08)
Short-term effects of chlorthalidone are unknown in low kidney function. The effects of 8-week treatment with 25-mg chlorthalidone on the top of ongoing treatment were compared between control hypertensives and low kidney function hypertensives as assessed by estimated glomerular filtration
Jerrica E Shuster et al.
Vascular health and risk management, 8, 381-387 (2012-06-30)
Azilsartan-chlorthalidone fixed combination is a new drug in the management of hypertension. Azilsartan has been shown to have greater blood pressure-lowering effects than other angiotensin-receptor blockers (ARBs), and the debate regarding the superiority of chlorthalidone over hydrochlorothiazide has been ongoing
Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications?
Nitin Khosla et al.
Journal of clinical hypertension (Greenwich, Conn.), 7(6), 354-356 (2005-08-10)
Sandra J Taler
Current hypertension reports, 10(4), 293-297 (2008-07-16)
For decades, diuretic therapy has been a cornerstone in treating hypertension, an approach supported by multiple randomized controlled trials demonstrating reduced morbidity and mortality from cardiovascular events. Yet controversy persists regarding the potential detrimental metabolic effects and side effects of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门